Overview

A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.

Status:
Recruiting

Trial end date:
2024-10-25

Target enrollment:

Participant gender:

Summary

A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH who have not been previously treated with complement inhibitor therapy. This study will enroll approximately 200 participants.

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Collaborator:

Chugai Pharmaceutical

Treatments:

Eculizumab